Biomerica, Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -2.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q4 FY26 | not reported | $-0.38 | not reported | not reported | |
| Q3 FY26 | not reported | $-0.44 | not reported | not reported | |
| Q2 FY26 | not reported | $-0.45 | not reported | not reported | |
| Q1 FY26 | not reported | $0.00 | not reported | not reported | |
| Q3 FY25 | not reported | $-0.06 | not reported | not reported | |
| Q2 FY25 | not reported | $-0.06 | not reported | not reported | |
| Q1 FY25 | not reported | $-0.08 | not reported | not reported | |
| Q4 FY24 | not reported | $-0.09 | not reported | not reported | |
| Q3 FY24 | not reported | $-0.11 | not reported | not reported | |
| Q2 FY24 | not reported | $-0.09 | not reported | not reported | |
| Q1 FY24 | not reported | $-0.07 | not reported | not reported | |
| Q4 FY23 | not reported | $-0.10 | not reported | not reported |
Back to BMRA overview · BMRA holders · BMRA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.